Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.42 |
| ▸ | CES2 | O00748 | 6/20 | 0.42 |
| ▸ | CES1 | P23141 | 6/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.37 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.37 |
| ▸ | ALB | P02768 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30368289 | 1.00 | ERN1 (0.42) | ERN1CES2CES1CA3CA6 | |
| SCHEMBL5512576 | 0.82 | ERN1 (0.48) | ERN1CES2CES1CA3CA6 | |
| SCHEMBL29597482 | 0.81 | ADRA2A (0.45) | ERN1CES2CES1CA3CA6 | |
| SCHEMBL669072 | 0.81 | CA3 (0.42) | ERN1CA3CA6CA5ACA9 | |
| SCHEMBL5506954 | 0.81 | ADRA2A (0.45) | ERN1CES2CES1CA3CA6 | |
| SCHEMBL29766667 | 0.81 | CA3 (0.42) | ERN1CA3CA6CA5ACA9 | |
| SCHEMBL932188 | 0.77 | ALDH1A1 (0.39) | ERN1CES2CES1CA3CA6 | |
| SCHEMBL19474701 | 0.77 | ERN1 (0.37) | ERN1CES2CES1CA3CA6 | |
| SCHEMBL1009105 | 0.77 | ALDH1A1 (0.38) | ERN1CA3CA6CA5ACA9 | |
| SCHEMBL22861620 | 0.77 | ERN1 (0.37) | ERN1CES2CES1CA3CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 391 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118598750-A | Fluorine-containing active ester compound and preparation method and application thereof | 广东工业大学 | 2024-09-06 | — | — | CN | claimed |
| CN-116789887-A | Ionic photoacid generator film-forming resin copolymer, preparation method and application | 中国科学院福建物质结构研究所 | 2023-09-22 | — | — | CN | claimed |
| US-20230142714-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2023-05-11 | — | — | US | claimed |
| US-10730826-B2 | Ketone inhibitors of lysine gingipain | Cortexyme, Inc. (US) | 2020-08-04 | — | — | US | claimed |
| EP-3512846-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2019-07-24 | — | — | EP | claimed |
| US-20190210960-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2019-07-11 | — | — | US | claimed |
| WO-2018053353-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2018-03-22 | — | — | WO | claimed |
| US-8952083-B2 | Fluorocopolymer composition and its production process | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | claimed |
| US-20140288249-A1 | Methods for Producing Polyolefins With Catalyst Systems | UNIVATION TECHNOLOGIES, LLC (US) | 2014-09-25 | — | — | US | claimed |
| EP-2776476-A1 | METHODS FOR PRODUCING POLYOLEFINS WITH CATALYST SYSTEMS | Univation Technologies, LLC (US) | 2014-09-17 | — | — | EP | claimed |
| US-20060004123-A1 | PHASE CHANGE INK PRINTING PROCESS | XEROX CORPORATION | 2006-01-05 | — | — | US | claimed |
| EP-1015641-A4 | SIMPLIFIED SEQUENTIAL CHEMILUMINESCENT DETECTION | LUMIGEN INC (US) | 2003-04-16 | — | — | EP | claimed |
| EP-0938677-A4 | CHEMILUMINESCENT DETECTION METHODS USING DUAL ENZYME-LABELED BINDING PARTNERS | LUMIGEN INC (US) | 2000-09-27 | — | — | EP | claimed |
| EP-1015641-A1 | SIMPLIFIED SEQUENTIAL CHEMILUMINESCENT DETECTION | LUMIGEN, INC. (US) | 2000-07-05 | — | — | EP | claimed |
| US-6068979-A | IMMOBILIZING TARGETS, CONTACTING WITH LABELED SPECIFIC BINDING PARTNERS FOR EACH TARGET, REACTING WITH SUBSTRATE FOR FIRST LABEL, DETECTING, REACTING WITH SUBSTRATE FOR SECOND ENZYME, DETECTING; ELIMINATES NEED FOR STRIPPING/REPROBING | LUMIGEN, INC. (US) | 2000-05-30 | — | — | US | claimed |
| WO-1999054503-B1 | SIMPLIFIED SEQUENTIAL CHEMILUMINESCENT DETECTION | LUMIGEN INC (US) | 1999-11-25 | — | — | WO | claimed |
| WO-1999054503-A1 | SIMPLIFIED SEQUENTIAL CHEMILUMINESCENT DETECTION | LUMIGEN, INC. (US) | 1999-10-28 | — | — | WO | claimed |
| EP-0938677-A1 | CHEMILUMINESCENT DETECTION METHODS USING DUAL ENZYME-LABELED BINDING PARTNERS | LUMIGEN, INC. (US) | 1999-09-01 | — | — | EP | claimed |
| US-5843666-A | Chemiluminescent detection methods using dual enzyer-labeled binding partners | LUMIGEN, INC. (US) | 1998-12-01 | — | — | US | claimed |
| WO-1998021586-A1 | CHEMILUMINESCENT DETECTION METHODS USING DUAL ENZYME-LABELED BINDING PARTNERS | LUMIGEN, INC. (US) | 1998-05-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142714-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | PHYKPL, ENPEP, PREP | ERN1 2625/4885CES2 1035/4885CES1 124/4885 |
| US-10730826-B2 | Ketone inhibitors of lysine gingipain | PHYKPL, ENPEP, PREP | ERN1 2625/4885CES2 1035/4885CES1 124/4885 |
| US-20190210960-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | PHYKPL, ENPEP, PREP | ERN1 2625/4885CES2 1035/4885CES1 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.